A major study involving over 750,000 pregnancies has shed new light on the potential risks of popular weight loss medications like Ozempic and Wegovy. Researchers found that women who took these medications for diabetes were more likely to give birth prematurely, but those taking them for weight loss did not experience this increased risk. The study suggests that the underlying condition of diabetes, rather than the medication itself, may be responsible for the higher risk of premature birth. The research team used Denmark's nationwide health registries to examine 756,636 pregnancies, focusing on preterm birth, pre-eclampsia, gestational diabetes, and other complications. They found that women prescribed GLP-1 medications for diabetes had a 70-84% higher risk of premature delivery compared to those not exposed to the medications. In contrast, women taking the medications for weight loss did not experience a significant increase in pregnancy complications. The study's findings have important implications for future research and clinical counseling, and highlight the need to distinguish between women taking GLP-1 medications for diabetes and those using them for weight control. While the results provide useful new information, the researchers emphasize that additional research is necessary before changing existing medical recommendations.